Incorporating Detection of Carbapenem Resistant Enterobacterales by Modified Carbapenem Inactivation Method (mCIM) and EDTA Carbapenem Inactivation Method (eCIM) in Surveillance Protocol, to Rationalize Antibiotic Therapy

Authors

Keywords:

Carbapenem-Resistant Enterobacterales, Carbapenemases, Metallo-Beta-Lactamases, Antimicrobial Resistance, Polymerase Chain Reaction

Abstract

Background: Carbapenem-resistant Enterobacterales (CRE) are an emerging global public health threat associated with multidrug resistance, prolonged hospitalization, increased healthcare costs, and elevated mortality. Early identification of carbapenemase mechanisms is essential for effective antimicrobial therapy, infection-control practices, and antimicrobial stewardship. Differentiation between metallo-β-lactamase (MBL) and serine β-lactamase (SBL) producers is clinically important because SBL-producing isolates may respond to ceftazidime-avibactam, whereas MBL-producing isolates often require combination therapy with ceftazidime-avibactam and aztreonam. Modified carbapenem inactivation method (mCIM) and EDTA-carbapenem inactivation method (eCIM) are economical phenotypic assays that can reliably detect and differentiate carbapenemase-producing Enterobacterales. This study aimed to incorporate mCIM and eCIM into surveillance protocols for characterization of CRE isolates and rationalization of antibiotic therapy.

 

Methods: This retrospective cross-sectional study included 45 archived multidrug-resistant Enterobacterales isolates resistant to carbapenems, obtained from urine, blood, exudates, tissue, wound swabs, and sterile body fluids. Isolates were revived and identified using standard biochemical tests. Carbapenemase production was screened using mCIM and differentiated into metallo-β-lactamase (MBL) and serine β-lactamase (SBL) producers using eCIM according to CLSI 2023 guidelines. Real-time PCR was performed for detection of blaNDM-1, blaOXA-48, blaKPC, blaIMP, and blaVIM genes.

 

Results: Among the 45 isolates studied, Klebsiella pneumoniae (62%) and Escherichia coli (34%) were the predominant organisms. Phenotypic testing showed 36 (80%) isolates as MBL producers, 5 (11%) as SBL producers, and 4 (9%) negative for carbapenemase production. RT-PCR detected blaNDM-1 in 36 isolates and blaOXA-48 in 5 isolates, while blaKPC, blaIMP, and blaVIM were not detected. Co-expression of blaNDM-1 and blaOXA-48 was observed in 22 isolates. Most isolates demonstrated high resistance to β-lactams and fluoroquinolones, while tigecycline and minocycline retained comparatively better activity. Majority of patients recovered, with an overall mortality rate of 13%.

Downloads

Published

2026-08-19

How to Cite

Murugan, H., Devi C, S., & D, S. (2026). Incorporating Detection of Carbapenem Resistant Enterobacterales by Modified Carbapenem Inactivation Method (mCIM) and EDTA Carbapenem Inactivation Method (eCIM) in Surveillance Protocol, to Rationalize Antibiotic Therapy . International Journal of Medical Students. Retrieved from https://ijms.info/IJMS/article/view/4880

Issue

Forthcoming

Section

Abstracts of the WCMSR

Categories

License

Copyright (c) 2026 Harinee Murugan, Sheela Devi C, Sridevi D

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  1. The Author retains copyright in the Work, where the term “Work” shall include all digital objects that may result in subsequent electronic publication or distribution.
  2. Upon acceptance of the Work, the author shall grant to the Publisher the right of first publication of the Work.
  3. The Author shall grant to the Publisher and its agents the nonexclusive perpetual right and license to publish, archive, and make accessible the Work in whole or in part in all forms of media now or hereafter known under a Creative Commons Attribution 4.0 International License or its equivalent, which, for the avoidance of doubt, allows others to copy, distribute, and transmit the Work under the following conditions:
    1. Attribution—other users must attribute the Work in the manner specified by the author as indicated on the journal Web site; with the understanding that the above condition can be waived with permission from the Author and that where the Work or any of its elements is in the public domain under applicable law, that status is in no way affected by the license.
    2. The Author is able to enter into separate, additional contractual arrangements for the nonexclusive distribution of the journal's published version of the Work (e.g., post it to an institutional repository or publish it in a book), as long as there is provided in the document an acknowledgment of its initial publication in this journal.
    3. Authors are permitted and encouraged to post online a prepublication manuscript (but not the Publisher’s final formatted PDF version of the Work) in institutional repositories or on their Websites prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. Any such posting made before acceptance and publication of the Work shall be updated upon publication to include a reference to the Publisher-assigned DOI (Digital Object Identifier) and a link to the online abstract for the final published Work in the Journal.
    4. Upon Publisher’s request, the Author agrees to furnish promptly to Publisher, at the Author’s own expense, written evidence of the permissions, licenses, and consents for use of third-party material included within the Work, except as determined by Publisher to be covered by the principles of Fair Use.
    5. The Author represents and warrants that:
      1. the Work is the Author’s original work;
      2. the Author has not transferred, and will not transfer, exclusive rights in the Work to any third party;
      3. the Work is not pending review or under consideration by another publisher;
      4. the Work has not previously been published;
      5. the Work contains no misrepresentation or infringement of the Work or property of other authors or third parties; and
      6. the Work contains no libel, invasion of privacy, or other unlawful matter.
    6. The Author agrees to indemnify and hold Publisher harmless from the Author’s breach of the representations and warranties contained in Paragraph 6 above, as well as any claim or proceeding relating to Publisher’s use and publication of any content contained in the Work, including third-party content.

Enforcement of copyright

The IJMS takes the protection of copyright very seriously.

If the IJMS discovers that you have used its copyright materials in contravention of the license above, the IJMS may bring legal proceedings against you seeking reparation and an injunction to stop you using those materials. You could also be ordered to pay legal costs.

If you become aware of any use of the IJMS' copyright materials that contravenes or may contravene the license above, please report this by email to contact@ijms.org

 

Infringing material

If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to contact@ijms.org